Literature DB >> 1672112

Functional receptors for the insulinotropic hormone glucagon-like peptide-I(7-37) on a somatostatin secreting cell line.

H C Fehmann1, J F Habener.   

Abstract

Glucagon-like peptide-I(7-37) [(GLP-I(7-37)] is an intestinal peptide hormone that has potent insulinotropic activities in vivo in response to oral nutrients, in the isolated perfused pancreas, and in vitro in cultured B cells. GLP-I(7-37) receptor binding and GLP-I(7-37)-induced cAMP generation and hormone secretion was studied using cell lines producing insulin/B cell (beta TC-1), glucagon/A cell (INR1G9) and somatostatin/D cell (RIN 1027-B2). [125I]GLP-I(7-37) bound specifically to both B and D cells but not to A cells. GLP-I(7-37) induced cAMP-formation in B and D cells with a maximum response at 10 nmol/l (B cells) or at 100 nmol/l (D cells). Insulin secretion from perifused B cells was stimulated by GLP-I(7-37) (maximum at 10 nmol/l) and 10 nmol/l GLP-I(7-37) released somatostatin from perifused D cells. GLP-I(7-37) did not influence cAMP or glucagon secretion from A cells. These data indicate that pancreatic B and D cells, but not the A cells are influenced directly by GLP-I(7-37) via binding to specific receptors. Our findings support a model of physiologic regulation of insulin secretion whereby GLP-I(7-37) released from the intestine in response to oral nutrients potently stimulates insulin secretion via an endocrine mechanism that in turn may be dampened by a feed-back suppression by the release of somatostatin. In addition, suppression of the secretion of glucagon, a hormone whose actions are counter-regulatory to those of insulin, may occur by paracrine mechanisms involving GLP-I(7-37)-mediated stimulation of both insulin and somatostatin secretion.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1672112     DOI: 10.1016/0014-5793(91)80182-3

Source DB:  PubMed          Journal:  FEBS Lett        ISSN: 0014-5793            Impact factor:   4.124


  17 in total

Review 1.  Glucagon-like peptide 1 (GLP-1).

Authors:  T D Müller; B Finan; S R Bloom; D D'Alessio; D J Drucker; P R Flatt; A Fritsche; F Gribble; H J Grill; J F Habener; J J Holst; W Langhans; J J Meier; M A Nauck; D Perez-Tilve; A Pocai; F Reimann; D A Sandoval; T W Schwartz; R J Seeley; K Stemmer; M Tang-Christensen; S C Woods; R D DiMarchi; M H Tschöp
Journal:  Mol Metab       Date:  2019-09-30       Impact factor: 7.422

2.  Exendin(9-39)amide is an antagonist of glucagon-like peptide-1(7-36)amide in humans.

Authors:  J Schirra; K Sturm; P Leicht; R Arnold; B Göke; M Katschinski
Journal:  J Clin Invest       Date:  1998-04-01       Impact factor: 14.808

3.  Mechanism of action of glucagon-like peptide-1(7-36NH2) in isolated rat pancreatic islets and abrogation of its effects in long-term incubations.

Authors:  K A Gronau; P L Brubaker
Journal:  Endocrine       Date:  1995-11       Impact factor: 3.633

Review 4.  The role of incretins in glucose homeostasis and diabetes treatment.

Authors:  Wook Kim; Josephine M Egan
Journal:  Pharmacol Rev       Date:  2008-12-12       Impact factor: 25.468

5.  Evidence that glucagon stimulates insulin secretion through its own receptor in rats.

Authors:  K Kawai; C Yokota; S Ohashi; Y Watanabe; K Yamashita
Journal:  Diabetologia       Date:  1995-03       Impact factor: 10.122

Review 6.  Glucagon-like peptide-1, a new hormone of the entero-insular axis.

Authors:  C Orskov
Journal:  Diabetologia       Date:  1992-08       Impact factor: 10.122

7.  Expression of the GLP-1 receptor in mouse, rat, and human pancreas.

Authors:  Ditte Tornehave; Peter Kristensen; John Rømer; Lotte Bjerre Knudsen; R Scott Heller
Journal:  J Histochem Cytochem       Date:  2008-06-09       Impact factor: 2.479

8.  Interaction of glucagon-like peptide-I (GLP-I) and galanin in insulin (beta TC-1)- and somatostatin (RIN T3)-secreting cells and evidence that both peptides have no receptors on glucagon (INR1G9)-secreting cells.

Authors:  H C Fehmann; M Janssen; B Göke
Journal:  Acta Diabetol       Date:  1995-10       Impact factor: 4.280

9.  Impaired cyclic AMP-dependent phosphorylation renders CREB a repressor of C/EBP-induced transcription of the somatostatin gene in an insulinoma cell line.

Authors:  M Vallejo; M E Gosse; W Beckman; J F Habener
Journal:  Mol Cell Biol       Date:  1995-01       Impact factor: 4.272

10.  Administration of pioglitazone alone or with alogliptin delays diabetes onset in UCD-T2DM rats.

Authors:  Bethany P Cummings; Ahmed Bettaieb; James L Graham; Kimber Stanhope; Fawaz G Haj; Peter J Havel
Journal:  J Endocrinol       Date:  2014-03-13       Impact factor: 4.286

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.